Review of our initial use of tomosynthesis-guided biopsy - How did it help? Dr Eman Hafez, Mrs Dianne Lennox, Dr Nerys Forester
Association of Breast Surgery ePoster Library. Hafez E. 05/13/19; 257078; P034
Dr. Eman Hafez
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P034
Topic: Breast screening
Introduction: Asuse ofdigital breasttomosynthesis(DBT) increases, there is a need for biopsy methods to sampleabnormalitiesonly onDBT. We have usedDBT since 2014,withDBT-biopsysinceAugust 2016,inscreening and symptomatic clinics.We have revieweduse of DBT-biopsy to assess themanagementrole of thisnewtechnique. Methods DBT-biopsiesbetween 08/2016 and 05/2018 identified from PACS. Imaging findings, management decisions andbiopsy outcomeswere reviewed. Results: 61 patients underwent DBT-biopsy over 21 months (57 screening, 2 recalled from surveillance mammography, 2incidentalcalcificationsin symptomatic patients). 21 masses, 21 distortions and 19 calcificationswere biopsied. Reasonsfor using DBT-biopsy:32wherethe areawasnot identified on USS,13 caseswhereDBT improved lesion accuracyand16for calcification where DBTwasoperatorpreferenceover stereotactic biopsy.Therewere 16 B5 diagnoses (9 B5a,7 B5b). In 8/16 cases,the mammographic lesionwas not identified by ultrasound. In 2,DBT-biopsyallowed more accurate lesion identification(multiple lesions or initial ultrasound biopsyat inaccurate site).6 cases (for calcification/clips)used DBT-biopsy atusersdiscretion.In 45 cases, the DBT-biopsy was benign.ConclusionDBT-biopsy is a useful tool in the assessment of breast disease. It is particularly helpful inassessment of subtle distortions which were ultrasound occult, and where lesion localisation is difficult on conventional imaging. In addition, it provides a ‘belt and braces' approach to low suspicion findings, where accurate benign biopsies can allow users to discharge the patient with increased confidence.
Topic: Breast screening
Introduction: Asuse ofdigital breasttomosynthesis(DBT) increases, there is a need for biopsy methods to sampleabnormalitiesonly onDBT. We have usedDBT since 2014,withDBT-biopsysinceAugust 2016,inscreening and symptomatic clinics.We have revieweduse of DBT-biopsy to assess themanagementrole of thisnewtechnique. Methods DBT-biopsiesbetween 08/2016 and 05/2018 identified from PACS. Imaging findings, management decisions andbiopsy outcomeswere reviewed. Results: 61 patients underwent DBT-biopsy over 21 months (57 screening, 2 recalled from surveillance mammography, 2incidentalcalcificationsin symptomatic patients). 21 masses, 21 distortions and 19 calcificationswere biopsied. Reasonsfor using DBT-biopsy:32wherethe areawasnot identified on USS,13 caseswhereDBT improved lesion accuracyand16for calcification where DBTwasoperatorpreferenceover stereotactic biopsy.Therewere 16 B5 diagnoses (9 B5a,7 B5b). In 8/16 cases,the mammographic lesionwas not identified by ultrasound. In 2,DBT-biopsyallowed more accurate lesion identification(multiple lesions or initial ultrasound biopsyat inaccurate site).6 cases (for calcification/clips)used DBT-biopsy atusersdiscretion.In 45 cases, the DBT-biopsy was benign.ConclusionDBT-biopsy is a useful tool in the assessment of breast disease. It is particularly helpful inassessment of subtle distortions which were ultrasound occult, and where lesion localisation is difficult on conventional imaging. In addition, it provides a ‘belt and braces' approach to low suspicion findings, where accurate benign biopsies can allow users to discharge the patient with increased confidence.
P034
Topic: Breast screening
Introduction: Asuse ofdigital breasttomosynthesis(DBT) increases, there is a need for biopsy methods to sampleabnormalitiesonly onDBT. We have usedDBT since 2014,withDBT-biopsysinceAugust 2016,inscreening and symptomatic clinics.We have revieweduse of DBT-biopsy to assess themanagementrole of thisnewtechnique. Methods DBT-biopsiesbetween 08/2016 and 05/2018 identified from PACS. Imaging findings, management decisions andbiopsy outcomeswere reviewed. Results: 61 patients underwent DBT-biopsy over 21 months (57 screening, 2 recalled from surveillance mammography, 2incidentalcalcificationsin symptomatic patients). 21 masses, 21 distortions and 19 calcificationswere biopsied. Reasonsfor using DBT-biopsy:32wherethe areawasnot identified on USS,13 caseswhereDBT improved lesion accuracyand16for calcification where DBTwasoperatorpreferenceover stereotactic biopsy.Therewere 16 B5 diagnoses (9 B5a,7 B5b). In 8/16 cases,the mammographic lesionwas not identified by ultrasound. In 2,DBT-biopsyallowed more accurate lesion identification(multiple lesions or initial ultrasound biopsyat inaccurate site).6 cases (for calcification/clips)used DBT-biopsy atusersdiscretion.In 45 cases, the DBT-biopsy was benign.ConclusionDBT-biopsy is a useful tool in the assessment of breast disease. It is particularly helpful inassessment of subtle distortions which were ultrasound occult, and where lesion localisation is difficult on conventional imaging. In addition, it provides a ‘belt and braces' approach to low suspicion findings, where accurate benign biopsies can allow users to discharge the patient with increased confidence.
Topic: Breast screening
Introduction: Asuse ofdigital breasttomosynthesis(DBT) increases, there is a need for biopsy methods to sampleabnormalitiesonly onDBT. We have usedDBT since 2014,withDBT-biopsysinceAugust 2016,inscreening and symptomatic clinics.We have revieweduse of DBT-biopsy to assess themanagementrole of thisnewtechnique. Methods DBT-biopsiesbetween 08/2016 and 05/2018 identified from PACS. Imaging findings, management decisions andbiopsy outcomeswere reviewed. Results: 61 patients underwent DBT-biopsy over 21 months (57 screening, 2 recalled from surveillance mammography, 2incidentalcalcificationsin symptomatic patients). 21 masses, 21 distortions and 19 calcificationswere biopsied. Reasonsfor using DBT-biopsy:32wherethe areawasnot identified on USS,13 caseswhereDBT improved lesion accuracyand16for calcification where DBTwasoperatorpreferenceover stereotactic biopsy.Therewere 16 B5 diagnoses (9 B5a,7 B5b). In 8/16 cases,the mammographic lesionwas not identified by ultrasound. In 2,DBT-biopsyallowed more accurate lesion identification(multiple lesions or initial ultrasound biopsyat inaccurate site).6 cases (for calcification/clips)used DBT-biopsy atusersdiscretion.In 45 cases, the DBT-biopsy was benign.ConclusionDBT-biopsy is a useful tool in the assessment of breast disease. It is particularly helpful inassessment of subtle distortions which were ultrasound occult, and where lesion localisation is difficult on conventional imaging. In addition, it provides a ‘belt and braces' approach to low suspicion findings, where accurate benign biopsies can allow users to discharge the patient with increased confidence.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}